Repligen Company Profile (NASDAQ:RGEN)

About Repligen (NASDAQ:RGEN)

Repligen logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RGEN
  • CUSIP: 75991610
  • Web:
  • Market Cap: $1.54 billion
  • Outstanding Shares: 37,356,000
Average Prices:
  • 50 Day Moving Avg: $41.71
  • 200 Day Moving Avg: $36.92
  • 52 Week Range: $26.16 - $46.81
  • Trailing P/E Ratio: 80.39
  • Foreward P/E Ratio: 55.77
  • P/E Growth: 2.82
Sales & Book Value:
  • Annual Revenue: $113.32 million
  • Price / Sales: 13.60
  • Book Value: $5.60 per share
  • Price / Book: 7.37
  • EBIDTA: $29.54 million
  • Net Margins: 26.00%
  • Return on Equity: 18.41%
  • Return on Assets: 11.29%
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 11.87%
  • Quick Ratio: 10.29%
  • Average Volume: 346,438 shs.
  • Beta: 1.3
  • Short Ratio: 7.49
Frequently Asked Questions for Repligen (NASDAQ:RGEN)

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) issued its earnings results on Thursday, August, 3rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen had a return on equity of 18.41% and a net margin of 26.00%. The business's revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.16 earnings per share. View Repligen's Earnings History.

When will Repligen make its next earnings announcement?

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Repligen.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $0.57-0.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.56. The company issued revenue guidance of $138-144 million, compared to the consensus revenue estimate of $128.09 million.

Where is Repligen's stock going? Where will Repligen's stock price be in 2017?

4 equities research analysts have issued 12-month price targets for Repligen's stock. Their forecasts range from $37.00 to $47.00. On average, they anticipate Repligen's stock price to reach $41.00 in the next year. View Analyst Ratings for Repligen.

Who are some of Repligen's key competitors?

Who are Repligen's key executives?

Repligen's management team includes the folowing people:

  • Karen A. Dawes, Independent Chairperson of the Board
  • Tony John Hunt, President, Chief Executive Officer, Director
  • Jon K. Snodgres, Chief Financial Officer
  • Howard Benjamin Ph.D., Vice President - Business Development
  • Nicolas M. Barthelemy, Independent Director
  • Glenn L. Cooper M.D., Independent Director
  • John G. Cox, Independent Director
  • Glenn P. Muir, Independent Director
  • Thomas F. Ryan Jr., Independent Director

Who owns Repligen stock?

Repligen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.19%), TimesSquare Capital Management LLC (6.93%), Vanguard Group Inc. (5.82%), FMR LLC (3.91%), Conestoga Capital Advisors LLC (3.79%) and State Street Corp (3.14%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Who sold Repligen stock? Who is selling Repligen stock?

Repligen's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, Dimensional Fund Advisors LP, Palisade Capital Management LLC NJ, Schwab Charles Investment Management Inc., Cornerstone Capital Management Holdings LLC., OxFORD Asset Management LLP and Bank of Montreal Can. Company insiders that have sold Repligen stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.

Who bought Repligen stock? Who is buying Repligen stock?

Repligen's stock was purchased by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, William Blair Investment Management LLC, PointState Capital LP, Castleark Management LLC, Vanguard Group Inc., Stephens Investment Management Group LLC, BlackRock Inc. and Marshall Wace North America L.P.. View Insider Buying and Selling for Repligen.

How do I buy Repligen stock?

Shares of Repligen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repligen's stock price today?

One share of Repligen stock can currently be purchased for approximately $41.27.

MarketBeat Community Rating for Repligen (NASDAQ RGEN)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Repligen (NASDAQ:RGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $41.00 (0.65% downside)

Analysts' Ratings History for Repligen (NASDAQ:RGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017William BlairInitiated CoverageOutperform -> OutperformLowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingHold$33.00 -> $40.00HighView Rating Details
6/23/2017Janney Montgomery ScottBoost Price Target$42.00 -> $47.00HighView Rating Details
4/21/2017First AnalysisReiterated RatingEqual Weight$40.00LowView Rating Details
12/18/2016StephensSet Price TargetBuy$37.00N/AView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 8/16/2015 forward)


Earnings History for Repligen (NASDAQ:RGEN)
Earnings by Quarter for Repligen (NASDAQ:RGEN)
Earnings History by Quarter for Repligen (NASDAQ RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017$0.15$0.20$31.72 million$32.40 millionViewListenView Earnings Details
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Repligen (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.55
2018 EPS Consensus Estimate: $0.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20174$0.09$0.15$0.13
Q4 20173$0.12$0.16$0.14
Q1 20182$0.14$0.17$0.16
Q2 20182$0.18$0.19$0.19
Q3 20181$0.18$0.18$0.18
Q4 20181$0.18$0.18$0.18
(Data provided by Zacks Investment Research)


Dividend History for Repligen (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Repligen (NASDAQ:RGEN)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 99.49%
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Repligen (NASDAQ:RGEN)
Latest Headlines for Repligen (NASDAQ:RGEN)
DateHeadline logoRepligen Corporation (RGEN) Raised to B- at TheStreet - August 15 at 8:34 PM logo Brokerages Anticipate Repligen Corporation (RGEN) Will Announce Quarterly Sales of $34.66 Million - August 15 at 11:55 AM logoSee what the IHS Markit Score report has to say about Repligen Corp. - August 15 at 6:43 AM logoRepligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : August 14, 2017 - August 15 at 6:43 AM logoRepligen Corp. – Value Analysis (NASDAQ:RGEN) : August 14, 2017 - August 15 at 6:43 AM logo$0.12 EPS Expected for Repligen Corporation (NASDAQ:RGEN) This Quarter - August 13 at 8:56 AM logoRepligen Corporation (RGEN) Lifted to "Buy" at Zacks Investment Research - August 12 at 5:42 PM logoFY2017 EPS Estimates for Repligen Corporation Increased by Analyst (NASDAQ:RGEN) - August 11 at 10:45 AM logoRepligen Corporation Expected to Post FY2020 Earnings of $1.08 Per Share (NASDAQ:RGEN) - August 10 at 1:50 PM logoFirst Analysis Brokers Reduce Earnings Estimates for Repligen Corporation (NASDAQ:RGEN) - August 10 at 9:20 AM logoQ3 2017 EPS Estimates for Repligen Corporation (RGEN) Reduced by Analyst - August 9 at 7:28 AM logoAbbVie (ABBV) versus Repligen Corporation (NASDAQ:RGEN) Critical Survey - August 7 at 9:08 AM logoQ3 2017 EPS Estimates for Repligen Corporation (NASDAQ:RGEN) Lifted by Analyst - August 7 at 7:34 AM logoRepligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of "Buy" from Analysts - August 5 at 7:06 AM logoRepligen's (RGEN) CEO Tony Hunt on Q2 2017 Results - Earnings Call Transcript - August 4 at 7:37 AM logoRepligen Reports Second Quarter 2017 Financial Results - August 4 at 7:37 AM logoRepligen beats Street 2Q forecasts - August 4 at 7:37 AM logoEdited Transcript of RGEN earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 4 at 7:37 AM logoRepligen Corporation (NASDAQ:RGEN) Announces Earnings Results, Beats Estimates By $0.05 EPS - August 3 at 8:52 PM logoRepligen Corporation (NASDAQ:RGEN) Releases FY17 Earnings Guidance - August 3 at 9:26 AM logoRepligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : July 31, 2017 - August 1 at 5:43 AM logo Analysts Expect Repligen Corporation (RGEN) Will Announce Quarterly Sales of $31.42 Million - July 28 at 7:55 PM logoRepligen to Report Second Quarter 2017 Financial Results - July 28 at 7:16 AM logoZacks: Analysts Expect Repligen Corporation (NASDAQ:RGEN) to Announce $0.15 Earnings Per Share - July 26 at 8:55 AM logoWilliam Blair Initiates Coverage on Repligen Corporation (NASDAQ:RGEN) - July 22 at 2:52 PM logoCritical Review: Repligen Corporation (RGEN) versus Salix Pharmaceuticals (SLXP) - July 13 at 8:10 AM logoRepligen Corporation (RGEN) Receives Average Rating of "Buy" from Analysts - July 11 at 10:06 AM logoRepligen Corporation (RGEN) Stock Rating Lowered by Zacks Investment Research - July 5 at 10:35 AM logoQ3 2017 EPS Estimates for Repligen Corporation (NASDAQ:RGEN) Decreased by First Analysis - July 3 at 7:58 AM logo Analysts Expect Repligen Corporation (RGEN) Will Post Quarterly Sales of $31.47 Million - July 1 at 7:38 AM logoZacks: Analysts Expect Repligen Corporation (RGEN) to Post $0.15 EPS - June 30 at 12:20 AM logoRepligen Corporation (RGEN) Given Hold Rating at Jefferies Group LLC - June 28 at 11:28 AM logoResearch Analysts Issue Forecasts for Repligen Corporation's Q4 2017 Earnings (RGEN) - June 28 at 8:28 AM logoRepligen (RGEN) Commences $100M Common Stock Offering - June 27 at 7:36 PM logoRepligen Corporation (RGEN) Updates On Merger Agreement with Spectrum - M&A Slideshow - June 27 at 7:36 PM logoRepligen Corporation Prices Public Offering of Shares of Common Stock - June 27 at 7:36 PM logoRepligen Corporation to Post Q3 2017 Earnings of $0.14 Per Share, Craig Hallum Forecasts (RGEN) - June 27 at 8:22 AM logoRepligen Corporation Announces Proposed Public Offering of Shares of Common Stock - June 27 at 7:49 AM logoRepligen Corporation (RGEN) Upgraded at BidaskClub - June 24 at 4:26 PM logoRepligen Corporation (RGEN) PT Raised to $47.00 at Janney Montgomery Scott - June 24 at 10:40 AM logoRepligen to buy filtration company Spectrum for $359 million in cash and stock - June 23 at 9:35 AM logoRepligen Corporation and Spectrum, Inc. to Join Forces - June 23 at 7:34 AM logoETFs with exposure to Repligen Corp. : June 19, 2017 - June 20 at 2:24 AM logoAnalyzing Repligen Corporation (RGEN) and Check-Cap (CHEK) - June 17 at 8:32 PM logoRepligen Corp. :RGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 3:31 PM logoRepligen Corporation (RGEN) Given Consensus Recommendation of "Buy" by Brokerages - June 14 at 4:54 PM logoRepligen Corporation (RGEN) Downgraded by BidaskClub - June 14 at 4:40 PM logoContrasting Repligen Corporation (RGEN) and DARA Biosciences (DARA) - June 14 at 12:45 PM logoRepligen Corporation (RGEN) Rating Increased to Buy at Zacks Investment Research - June 14 at 7:42 AM logoRepligen Co. (RGEN) Expected to Post Quarterly Sales of $31.47 Million - June 7 at 8:50 AM



Repligen (RGEN) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by Staff